Malta - English - Medicines Authority

alfred gera & sons limited 10 triq il-masgar, qormi qrm3217, malta - paracetamol, codeine phosphate, hemihydrate - film-coated tablet - paracetamol 500 mg codeine phosphate hemihydrate 12.8 mg - analgesics

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - phenylephrine hydrochloride, quantity: 5 mg; codeine phosphate hemihydrate, quantity: 9 mg; paracetamol, quantity: 499.9996 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; stearic acid; povidone; silicon dioxide; pregelatinised maize starch - temporary relief from symptoms of colds & flu: body aches and pains, fever, headache, nasal congestion, runny nose.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - codphos tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - codeine phosphate hemihydrate,ibuprofen -

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - codeine phosphate - tablet - codeine phosphate 30 mg - analgesics

United Kingdom - English - myHealthbox

actavis group ptc ehf - codeine phosphate hemihydrate/paracetamol - film-coated tablets - 60/1000mg - codeine, combinations excl. psycholeptics - for the relief of moderate to severe pain in adults and adolescents 16 years and older. codeine is indicated in patients 16 years and older for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen

United States - English - NLM (National Library of Medicine)

pro-pharma, llc - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), dexchlorpheniramine maleate (unii: b10yd955qw) (dexchlorpheniramine - unii:3q9q0b929n), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - codeine phosphate 9 mg in 5 ml - temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: - cough due to minor throat and bronchial irritation - nasal congestion - reduces swelling of nasal passages - runny nose - sneezing - itching of the nose or throat - itchy, watery eyes

United States - English - NLM (National Library of Medicine)

nexgen pharma, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - codeine phosphate 54.3 mg - codeine phosphate and chlorpheniramine maleate is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. important limitations of use not indicated for pediatric patients under 18 years of age [see use in special population (8.4)] patients with known hypersensitivity to codeine, chlorpheniramine or any of the inactive ingredients of codeine phosphate and chlorpheniramine maleate. persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to codeine. teratogenic effects pregnancy category c there are no adequate and well-controlled studies of codeine phosphate and chlorpheniramine maleate in pregnant women. reproductive toxicity studies have not been conducted with codeine phosphate and chlorpheniramine maleate; however, studies are available with individual active ingredients or related active ingredients. because animal reproduction studies are not always predictive of human response, co

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine - unii:q830pw7520), butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - butalbital, acetaminophen, caffeine, and codeine phosphate capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of butalbital, acetaminophen, caffeine, and codeine phosphate capsules in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. butalbital, acetaminophen, caffeine, and codeine phosphate capsules is contraindicated under the following conditions: −  hypersensitivity or intolerance to acetaminophen, caffeine, butalbital, or codeine. −  patients with porphyria. butalbital, acetaminophen, caffeine, and codeine phosphate capsules is controlled by the drug enforcement administration and is classified under schedule iii. codeine codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. psychological dependence, physical dependence,